Offin Michael, Fitzgerald Bailey, Zauderer Marjorie G, Doroshow Deborah
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA.
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
J Cancer Metastasis Treat. 2023;9. doi: 10.20517/2394-4722.2022.140. Epub 2023 May 30.
Despite our growing understanding of the genomic landscape of diffuse pleural mesotheliomas (DPM), there has been limited success in targeted therapeutic strategies for the disease. This review summarizes attempts to develop targeted therapies in DPM, focusing on the following targets being clinically explored in recent and ongoing clinical trials: vascular endothelial growth factor, mesothelin, BRCA1-associated protein 1, Wilms tumor 1 protein, NF2/YAP/TAZ, CDKN2, methylthioadenosine phosphorylase, v-domain Ig suppressor T-cell activation, and argininosuccinate synthetase 1. Although preclinical data for these targets are promising, few have efficaciously translated to benefit our patients. Future efforts should seek to expand the availability of preclinical models that faithfully recapitulate DPM biology, develop clinically relevant biomarkers, and refine patient selection criteria for clinical trials.
尽管我们对弥漫性胸膜间皮瘤（DPM）的基因组格局有了越来越多的了解，但针对该疾病的靶向治疗策略取得的成功有限。本综述总结了在DPM中开发靶向治疗的尝试，重点关注近期和正在进行的临床试验中正在临床探索的以下靶点：血管内皮生长因子、间皮素、BRCA1相关蛋白1、肾母细胞瘤1蛋白、NF2/YAP/TAZ、CDKN2、甲硫腺苷磷酸化酶、v结构域Ig抑制T细胞活化和精氨酸琥珀酸合成酶1。尽管这些靶点的临床前数据很有前景，但很少有能有效转化为使我们的患者受益的疗法。未来的努力应致力于扩大能忠实地概括DPM生物学特性的临床前模型的可用性，开发临床相关的生物标志物，并完善临床试验的患者选择标准。
